Recent global policies (i.e., Joint Clinical Assessment, Inflation Reduction Act, FDA Data Requirements), evolving stakeholder expectations, and enhanced focus on sustained access have intensified requirements for demonstrating value. Against this landscape, life science companies need to evolve their value demonstration strategies to be successful in this dynamic environment. During this session, panelists will discuss methods to create a coherent value strategy that considers key questions, such as:

• How do these new external requirements and changing internal constraints (compressed timelines, new stakeholders, etc.) shift evidence generation and value demonstration?
• How will the evolving scientific landscape and the development of more targeted therapies drive change in value assessment and dissemination?
• How do these changes drive new trade-offs, and how does evidence strategy decision-making need to change in response?
• What value strategies should be incorporated into lifecycle planning to drive sustained access?